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INTRODUCTION
Renal cell carcinoma (RCC) is the most common malig-
nancy of the adult kidney, comprising 3% of all human can-
cers (1). The current renal tumor classification system is based
on histology, as well as genetic difference (2, 3). More than
90% of clinically notable lesions can be diagnosed as one of
the common subtypes of renal epithelial tumors: clear cell
RCC, papillary RCC, chromophobe RCC, and renal onco-
cytomas. Recent study suggested that clear cell RCC has the
highest rate of metastasis and poorest survival among com-
mon renal malignancies. Chromophobe RCC have relatively
indolent biologic behavior (4). 
Chromophobe RCC accounts for 5% of the epithelial tu-
mors of the kidney (5). It has been suggested that the cells
of chromophobe RCC are related to the normal intercalated
cells of the collecting ducts, as it is ultra-structurally charac-
terized by the presence of numerous cytoplasmic vesicles
resembling those observed in intercalated cells (6). The diag-
nosis of chromophobe RCC is sometimes difficult because
histological features of chromophobe RCC are similar to those
of oncocytoma and the granular variant of clear cell RCC.
Ancillary immunohistochemical or molecular markers are
often needed to make an accurate subtyping of renal tumors.
A number of immunohistochemical and histochemical
markers have been reported to be useful in making a diag-
nosis of chromophobe RCC. Markers for keratin 7, keratin
20, CD10, epithelial membrane antigen, vimentin, anti-mi-
tochondrial antibody, and Hale’s colloidal iron stain have been
proposed as having some degree of specificity in diagnosing
chromophobe RCC (7-12). Recently, it has been reported
that parvalbumin is also specific for chromophobe RCC, which
may make it useful as a marker in the differential diagnosis
of chromophobe RCC and other subtypes of RCC (13). Par-
valbumin, a calcium-binding protein, is selectively expressed
in the collecting ducts of the fetal kidney and in the distal
nephron of the adult kidney. 
Claudin was discovered as a family of tight junction pro-
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Claudin-7 is Highly Expressed in Chromophobe Renal Cell Carcinoma
and Renal Oncocytoma
Claudin-7 has recently been suggested to be a distal nephron marker. We tested
the possibility that expression of claudin-7 could be used as a marker of renal tumors
originating from the distal nephron. We examined the immunohistochemical expres-
sion of claudin-7 and parvalbumin in 239 renal tumors, including 179 clear cell renal
cell carcinoma (RCC)s, 29 papillary RCCs, 20 chromophobe RCCs, and 11 renal
oncocytomas. In addition, the methylation specific-PCR (MSP) of claudin-7 was per-
formed. Claudin-7 and parvalbumin immunostains were positive in 3.4%, 7.8% of
clear cell RCCs, 34.5%, 31.0% of papillary RCCs, 95.0%, 80.0% of chromophobe
RCCs, and 72.7%, 81.8% of renal oncocytomas, respectively. The sensitivity and
specificity of claudin-7 in diagnosing chromophobe RCC among subtypes of RCC
were 95.0% and 92.3%. Those of parvalbumin were 80.0% and 88.9%. The expres-
sion pattern of claudin-7 was mostly diffuse in chromophobe RCC and was either
focal or diffuse in oncocytoma. All of the cases examined in the MSP revealed the
presence of unmethylated promoter of claudin-7 without regard to claudin-7 immu-
noreactivity. Hypermethylation of the promoter might not be the underlying mecha-
nism for loss of its expression in RCC. Claudin-7 can be used as a useful diagnos-
tic marker in diagnosing chromophobe RCC and oncocytoma. 
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teins (14), and there are 20 known members of the claudin
family (15). Recently, it was demonstrated that claudin-7 is
a distal nephron marker (16). Claudin-7 has not been exten-
sively studied as an immunohistochemical marker in diag-
nosing renal tumors of distal nephron origin, such as chro-
mophobe RCC or oncocytoma.
In the present study, we tested whether the presence of
claudin-7 could be used as a marker of renal tumors origi-
nating from the distal nephron. We examined 239 cases of
renal tumors using immunohistochemical stains for claudin-
7 and parvalbumin. Furthermore, methylation specific-PCR
(MSP) was performed to see whether the expression of claudin-
7 was regulated by hyper-methylation of the promoter.
MATERIALS AND METHODS
Study materials
The study materials consisted of 239 paraffin-embedded
tissues of primary renal tumors and one fetal kidney. Tissue
samples were obtained from the surgical pathology archives
of the Department of Pathology at Chonnam National Uni-
versity Hospital, Seoul National University Hospital, Yonsei
University Severans Hospital, Dong-A University Hospital,
and Asan Medical Center from the years 1996 to 2004. Of
239 tumors, 179 were clear cell RCC, 29 were papillary RCC,
20 were chromophobe RCC, and 11 were renal oncocytoma.
Of the 239 cases, 42 were obtained on standard glass slides
and 197 cases on a tissue microarray (TMA), which was con-
structed by the Korean Genitourinary Pathology Study Group.
The diameter of the core was 1 mm, and 3 cores had been
obtained in each case. The TMA contained 166 clear cell RCC,
20 papillary RCC, and 11 chromophobe RCC. Chromophobe
RCC included 14 cases of typical variant and 6 cases of eosi-
nophilic variant carcinoma (17). All tumors were classified
according to standard international criteria (18, 19). For the
228 RCC cases, staging was performed according to the TNM
system, and grading according to the system of Fuhrman et al.
(20). For the 179 clear cell RCC cases, 98 tumors were stage
T1 (54.7%), 42 stage T2 (23.5%), 38 stage T3 (21.2%), and
1 stage T4 (0.6%). Eighteen tumors were grade 1 (10.1%),
100 grade 2 (55.9%), 50 grade 3 (27.9%), and 11 grade 4
(6.1%). For the 29 papillary RCC cases, 15 tumors were stage
T1 (51.7%), 7 stage T2 (24.1%), and 7 stage T3 (24.1%).
One tumor was grade 1 (3.4%), 12 grade 2 (41.4%), 14 grade
3 (48.3%) and 2 grade 4 (6.9%). For the 20 chromophobe
RCC cases, 15 tumors were stage T1 (75.0%), 4 stage T2
(20.0%), and 1 stage T3 (5.0%). Four tumors were grade 1
(20.0%), 13 grade 2 (65.0%), and 3 grade 3 (15.0%). 
Immunohistochemical stain
Tissue sections in glass slides were de-paraffinized with
xylene, hydrated in serially diluted alcohol, and then im-
mersed in 3% H2O2 in order to quench endogenous peroxi-
dase activity. Antigen retrieval was performed using citrate
buffer (Antigen Retrieval Citra; Biogenex, San Ramon, CA,
U.S.A.) with a pressure cooker. The sections were then incu-
bated with anti-claudin-7 antibody (rabbit polyclonal; 1:200
dilution; Zymed, CA, U.S.A.) and anti-parvalbumin anti-
body (mouse polyclonal; 1:200 dilution; Chemicon Interna-
tional, CA, U.S.A.). The LSAB+ (Dakocytomation, Glostrup,
Denmark) detection system was applied. The tissue sections
were incubated with horseradish peroxidase (HRP)-conju-
gated streptavidin and the color reaction was developed with
liquid 3,3′ -diaminobenzidine as a chromogen, and counter-
stained with hematoxylin. 
Methylation-specific PCR (MSP)
We investigated the promoter region of the claudin-7 gene
by MSP on the DNA obtained from five cases of clear cell
RCC and three cases of chromophobe RCC. Four of the five
clear cell RCCs were negative for claudin-7 immunostain,
and one case was positive for claudin-7. All of the chromo-
phobe RCCs were positive for claudin-7. MSP of claudin-7
was performed as described in a previous study (21). The
primers specific for un-methylated DNA were 5′ -TGGG-
GAAAGGGTGGTGTTG-3′ (sense) and 5′ -TTACCCAA-
TTTTAACCACCAC-3′ (antisense), yielding a 182 bp prod-
uct. Primers specific for methylated DNA were 5′ -GACGT-
TAGGTTATTTTCGGTC-3′ (sense) and 5′ -AAACGCGT-
TTCTAAACGCCG-3′ (antisense), yielding a 220 bp prod-
uct. The genomic DNA (10  g) treated with 40 U of CpG
methylase (New England Biolabs, MA, U.S.A.) at 37℃ for
two hours. It was used as a positive control of methylated
DNA. The CCRF-CEM cell (Korean Cell Line Bank, Seoul,
Korea), an acute lymphoblastic leukemia cell line, was seed-
ed in a 100 mm plate at a density of 1×106cells. After 24 hr,
cells were treated with 10  M of 5-azacytidine (Sigma, St.
Louis, MO, U.S.A.) for 7 days, and the genomic DNA was
isolated. It was used as a control of unmethylated DNA. All
of the genomic DNA (1  g) were treated with sodium bisul-
fite as previously des- cribed before PCR amplification (22).
Interpretation of immunohistochemical stain
All slides were evaluated by light microscopy with a semi-
quantitative estimation. Immunoreactivity was assessed with-
out previous knowledge of the clinico-pathologic features.
Membranous staining for claudin-7, and cytoplasmic stain-
ing for parvalbumin were analyzed. The extent of immuno-
expression was sub-classified as: focal, <25% of tumor cells;
and diffuse, 25-100% of tumor cells. Each tumor was sepa-
rately examined by three pathologists, and cases with discre-
pant scores were discussed until consensus unity was achieved. Claudin-7 in Chromophobe Renal Cell Carcinoma and Renal Oncocytoma 307
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Fig. 1. Immunohistochemical stains of claudin-7 and parvalbumin. Hematoxylin and eosin stains of normal renal cortex (A), clear cell RCC
(B), papillary RCC (C), chromophobe RCC (D), and renal oncocytoma (E) are shown. Claudin-7 is expressed in the distal nephron of normal
renal cortex with a distinct membranous pattern (F). It is diffusely expressed in papillary RCC (H) and chromophobe RCC (I), and is focally
expressed in oncocytoma (J). It is not expressed in clear cell RCC (G). Parvalbumin is expressed in the cytoplasm of the distal nephron
of normal renal cortex (K). It is diffusely expressed in papillary RCC (M), chromophobe RCC (N), and oncocytoma (O). It is not expressed
in conventional RCC (L) (A-O, ×200).
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Statistical analysis 
Statistical tests for significant differences in the intensity
and extent of immunostains between standard slides and TMA
were performed using Wilcoxon two sample test. Statistical
analysis for significant differences in expression of claudin-7
and parvalbumin between chromophobe RCC and oncocy-
toma were performed using a two-tailed Fisher’s exact test,
with a significant p-value set as <0.05. Statistical comparisons
were performed using SPSS, version 12.0 software (SPSS,
Chicago, IL, U.S.A.).
RESULTS
Immunohistochemical stain
In the normal fetal and adult kidney, claudin-7 immunore-
activity was limited to the distal tubules and collecting ducts,
displaying a distinctive membranous pattern, and parvalbu-
min was expressed in the cytoplasm at the same site (Fig. 1).
The results describing the immunoreactivity of claudin-7
and parvalbumin are presented in Table 1 and 2. Positive
immunoreactivity for claudin-7 was shown in 3.4% of clear
cell RCCs (6 of 179 cases), 34.5% of papillary RCCs (10 of
29 cases), 95.0% of chromophobe RCCs (19 of 20 cases), and
72.7% of renal oncocytomas (8 of 11 cases). Positive immu-
noreactivity for parvalbumin was shown in 7.8% of clear cell
RCCs (14 of 179 cases), 31.0% of papillary RCCs (9 of 29
cases), 80.0% of chromophobe RCCs (16 of 20 cases), and
81.8% of renal oncocytomas (9 of 11 cases). The intensity
and extent of claudin-7 or parvalbumin were not different
between the standard glass slide and TMA (p>0.5). And, for
each subtype of RCC, the expression of claudin-7 or parval-
bumin was not correlated with TNM stage and nuclear grade.
The expression of claudin-7 and parvalbumin was similar in
all of the tumors (Fig. 1). Claudin-7 and parvalbumin were
highly expressed in both chromophobe RCC and oncocytoma.
Although the expression rate of the two proteins was low in
clear cell RCCs and papillary RCCs, immunoreactivity was
quite obvious in some cases. The positive immunoreactivity
of both claudin-7 and parvalbumin was shown in two cases
of clear cell RCC and five cases of papillary RCC. None of
these seven cases revealed any histologic features resembling
chromophobe RCC. Claudin-7 and parvalbumin were not
expressed in one, and in four cases of chromophobe RCC,
respectively. At least one of two immunostains was positive
in all cases of chromophobe RCC. Although both claudin-7
and parvalbumin were highly expressed in chromophobe
RCC and oncocytoma, the expression pattern of claudin-7
was significantly different (p=0.03). The majority of chro-
mophobe RCC revealed a diffuse staining pattern, whereas
oncocytoma revealed either a focal or a diffuse pattern. The
expression pattern of parvalbumin was not significantly dif-
ferent between chromophobe RCC and oncocytoma (p=0.22).
The sensitivity and specificity of claudin-7 and parvalbu-
min immunostaining in making a diagnosis of chromophobe
RCC was evaluated. Claudin-7 had a sensitivity of 95.0%
and a specificity of 92.3%. These same measures for parval-
bumin were lower than those of claudin-7, with a sensitivi-
ty of 80.0% and a specificity of 88.9%. 
Methylation-specific PCR
To determine if claudin-7 expression is controlled by hyper-
methylation-mediated silencing of the promoter, we per-
formed MSP analysis on the extracted DNAs of claudin-7
positive and claudin-7 negative RCCs. All of the cases reveal-
ed the presence of unmethylated promoter sequences of clau-
din-7 (Fig. 2). The evidence provided by MSP supports the
idea that hyper-methylation of the promoter might not be
the underlying mechanism for the loss of claudin-7 expres-
sion in RCC; thus alternative mechanisms should be inves-
Fig. 2. Methylation-specific PCR of claudin-7. Primer sets used for
amplification are designated as un-methylated (U), and methy-
lated (M). The methylated control DNA (MC), and un-methylated
control DNA (UMC) are designated. The smaller molecular weight
fragments seen in the U and M lanes are primer dimers. 
Renal tumors
Clear cell 
RCC
(n=179)
Papillary 
RCC
(n=29)
Chromphobe
RCC
(n=20)
Oncocy-
toma
(n=11)
Number of  6 (3.4%) 10 (34.5%) 19 (95.0%) 8 (72.7%)
positive cases
Extent
Focal 5/6 (83.3%) 6/10 (60.0%) 3/19 (15.8%) 5/8 (62.5%)
Diffuse 1/6 (16.7%) 4/10 (40.0%) 16/19 (84.2%) 3/8 (37.5%)
Table 1. Immunoreactivity of claudin-7 in renal epithelial tumors
Renal tumors
Clear cell 
RCC
(n=179)
Papillary 
RCC
(n=29)
Chromphobe
RCC
(n=20)
Oncocy-
toma
(n=11)
Number of  14 (7.8%) 9 (31.0 %) 16 (80.0%) 9 (81.8%)
positive cases
Extent
Focal 12/14 (85.7%) 6/9 (66.7%) 5/16 (31.3%) 5/9 (55.6%)
Diffuse 2/14 (14.3%) 3/9 (33.3%) 11/16 (68.8%) 4/9 (44.4%)
Table 2. Immunoreactivity of parvalbumin in renal epithelial tumors
Case 
number
Primer U
1T
CLDN7 Immunostain (-)
Conventional RCC Control
Chromophobe 
RCC
M U
2T
M U
4T
M U
6T
M U
12T
M U
25T
M U
26T
M U
27T
M U
MC
220 bp
180 bp
M U
UMC
M
CLDN7 Immunostain (+)tigated in evaluating primary RCC.
DISCUSSION
Shortly after the Heidelberg classification of kidney tumors
was published, pathologists and clinicians noted that chro-
mophobe RCC had a distinctly better prognosis than that
of other RCC types (7). In this sudy, the nuclear grade and
stage in chromophobe RCC cases was lower than those of
other RCCs. It is imperative to make a diagnosis of chromo-
phobe RCC correctly, due to the obvious prognostic impli-
cations. In this study, we demonstrated that claudin-7 and
parvalbumin are specifically expressed in chromophobe RCC
and oncocytoma, and the sensitivity and specificity of claudin-
7 were higher than those of parvalbumin in the diagnosis of
chromophobe RCC from other RCC types. 
In this study, claudin-7 was expressed in the cell membrane
of distal tubules and collecting ducts. Claudins are compo-
nents of the tight junctions between epithelial cells. The tight
junction structure is important for restricting lateral effusion
of lipids and membrane proteins, thereby physically defining
the border between the apical and basolateral components
of the cell. To date, more than 20 claudins have been identi-
fied, and some show tissue specificity. A high-level of claudin-
4 was detected in cells of the colon, an intermediate level was
detected in prostate, placenta, lung, and pancreastic tissue,
and low-levels were found in samples of the small bowel, kid-
ney, and uterus (23). The tissue specificity of claudins strongly
suggests that they may have other functions, in addition to
being structural components of tight junctions (23). In renal
tumors, claudin-7 was expressed in chromophobe RCC and
oncocytoma, which supports the suggestion that these tumors
originate from cells of the distal tubule and collecting duct.
Parvalbumin, a high affinity calcium-ion binding protein,
is expressed in high levels in fast-contracting muscles, and
is found at lower levels in brain and several endocrine tissues.
It is related in structure and function to calmodulin and tro-
ponin C (24). The distribution of parvalbumin in the kidney
matches fairly well with that of calcium receptors in the dis-
tal tubule and the proximal collecting duct, where the fine
regulation of calcium re-adsorption takes place (13). The
presence of parvalbumin was reported in most of the chro-
mophobe RCCs with intense cytoplasmic staining (7, 13).
In this study, the sensitivity and specificity were 80.0% and
88.9%, respectively. 
The expression pattern of claudin-7 was significantly dif-
ferent between chromophobe RCC and oncocytoma. Chro-
mophobe RCC revealed diffuse pattern in 84.2% and focal
pattern in 15.8%. Oncocytoma revealed diffuse pattern in
37.5% and focal pattern in 62.5%. Hale’s colloidal iron stain
has been considered to be the most useful marker for mak-
ing a differential diagnosis between two tumors (10). But,
staining is technically demanding, and interpretation with-
out experience is rather difficult. Therefore, the claudin-7
immunohistochemical stain could be used as a supplemen-
tary method of Hale’s colloidal iron stain for making a dif-
ferential diagnosis between two tumors. 
Young et al. demonstrated that proximal nephron mark-
ers, such as megalin,  -methylacyl CoA racemase were over-
expressed in clear cell and papillary RCC, whereas distal ne-
phron markers, such as beta-defensin 1 and claudin-7 were
overexpressed in chromophobe RCC and oncocytoma (25).
Claudin-7 and parvalbumin were distinctly expressed in a
few cases of clear cell RCC. And they were expressed in 34.5
% and 31.0% in papillary RCC, respectively. In concordance
with our results, the distal nephron markers, parvalbumin
and beta-defensin, and a proximal nephron marker, vimentin,
can be expressed in some cases of papillary RCCs (25). These
findings may reflect the histogenesis of papillary renal cell
carcinoma, which has been related to either proximal or dis-
tal nephron epithelium (25, 26). Claudin-7 and parvalbumin
were not expressed in one case, nor in four cases of chromo-
phobe RCCs, respectively. They were not expressed in three
cases, nor two cases of renal oncocytomas, respectively. It is
also possible that some tumors in these categories do not show
differentiation towards the distal nephron in spite of charac-
teristic histologic features.
Our result suggested that claudin-7 expression might not
be controlled by unmethylation/hyper-methylation of its
promoter. Similar results on hyper-methylation of claudin-7
were reported in infiltrating ductal carcinoma of breast. Al-
though silencing of claudin-7 was correlated with promoter
hyper-methylation in breast cancer cell lines, it did not do so
in infiltrating ductal carcinoma of the breast (21). Further
evaluation is needed to clarify the epigenetic regulation of
claudin-7 expression. 
In conclusion, we found that claudin-7 could be used as a
valuable diagnostic marker in the diagnosis of chromophobe
RCC and oncocytoma. 
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